ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

CHF10073

A development code. Also written as “CHF10073 low dose”, “CHF10073 high dose” and “CHF10073 (Part 1 - SAD)”.

Its studies are mostly in Idiopathic Pulmonary Fibrosis · Pulmonary Fibrosis, led by Chiesi Farmaceutici.

Furthest: phase 1, since Nov 26, 20242 company-led studies, 1 open or runningNext primary completion: Aug 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chiesi Farmaceutici21 open or runningphase 1since Nov 26, 2024Nov 26, 2024Aug 2027phase 1 · NCT07876284

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 26, 2024First study: phase 1 study in Pulmonary FibrosisFirst studyNCT06746064 · 155 enrolled · Belgium
  2. Oct 9, 2026Phase 1 study in Idiopathic Pulmonary FibrosisNCT07876284 · 18 planned

Ahead

  1. Aug 2027Primary completion: phase 1 study in Idiopathic Pulmonary FibrosisNCT07876284

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07876284Idiopathic Pulmonary Fibrosis1Not yet recruitingAug 202718
NCT06746064Pulmonary Fibrosis · Belgium1CompletedFeb 4, 2026155

How it is read

Names in the registry

  • “CHF10073 low dose”, 1 entry
  • “CHF10073 high dose”, 1 entry
  • “CHF10073 (Part 1 - SAD)”, 1 entry
  • “CHF10073 (Part 2 - MAD)”, 1 entry
  • “CHF10073 (Part 3)”, 1 entry

Codes read as this program: CHF10073.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.